Cowie, Martin R. http://orcid.org/0000-0001-7457-2552
Fisher, Miles
Article History
Accepted: 10 June 2020
First Online: 14 July 2020
Competing interests
: M.R.C. is a non-executive director of the National Institute for Health and Care (NICE) but this Review should not be taken as an official position of that organization on the role of SGLT2 inhibitors. M.R.C. has provided consultancy advice and received honoraria for lecturing at educational events from AstraZeneca, Boehringer Ingelheim, Eli Lilly and NovoNordisk. M.F. has provided consultancy advice and received honoraria for lecturing at educational events from AstraZeneca, Boehringer Ingelheim, Eli Lilly, Janssen, NAPP, NovoNordisk and Sanofi. M.F. is on the data and safety monitoring board for the phase III development programme for sotagliflozin.